SCHEMBL29595423

SCHEMBL29595423

CC1CC=NN1C(=O)c1cccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 5/20 0.66
ALDH1A1 P00352 2/20 0.52
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47
MAPK1 P28482 1/20 0.46
PIK3CD O00329 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 2/20 0.44
APP P05067 1/20 0.44
HCAR3 P49019 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL179758 1.00 RIPK1 (0.66) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL179757 1.00 RIPK1 (0.66) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL2481688 1.00 RIPK1 (0.66) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9378435 0.82 RIPK1 (0.62) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9378268 0.82 RIPK1 (0.62) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9378120 0.81 RIPK1 (0.88) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9379168 0.81 RIPK1 (0.63) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9383151 0.80 RIPK1 (0.59) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL12204414 0.80 RIPK1 (0.62) RIPK1ALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL9370134 0.80 RIPK1 (1.00) RIPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146254-A1 Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications SEGENA CORPORATION S.A. (UY) 2026-05-28 US disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
EP-4622674-A1 ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS SEGENA CORPORATION S.A. (UY) 2025-10-01 EP disclosed
US-20250092001-A1 NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME UNIV DREXEL (US) 2025-03-20 US disclosed
US-20250057808-A1 COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS UNIVERSITY OF TOLEDO 2025-02-20 US disclosed
US-12162891-B2 Glutamate transporter activators and methods using same DREXEL UNIVERSITY (US) 2024-12-10 US disclosed
EP-4469440-A1 NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME Drexel University (US) 2024-12-04 EP disclosed
EP-3210626-B1 CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY BIOLITEC HOLDING GMBH & CO KG (AT) 2024-11-27 EP disclosed
CN-118946550-A Novel excitatory amino acid glutamate transport modulators and methods of use thereof 德雷克塞尔大学 2024-11-12 CN disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-20240228482-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-117751115-A Compounds, compositions, and methods of treating cancer 热点治疗公司 2024-03-22 CN disclosed
EP-4323358-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER Hotspot Therapeutics, Inc. (US) 2024-02-21 EP disclosed
WO-2023146831-A1 NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME DREXEL UNIVERSITY (US) 2023-08-03 WO disclosed
US-20220402938-A1 GLUTAMATE TRANSPORTER ACTIVATORS AND METHODS USING SAME UNIV DREXEL (US) 2022-12-22 US disclosed
WO-2022221704-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. (US) 2022-10-20 WO disclosed
US-20220267308-A1 Modulators of Excitatory Amino Acid Transporters and Methods Using Same DREXEL UNIVERSITY 2022-08-25 US disclosed
US-11377452-B2 Glutamate transporter activators and methods using same DREXEL UNIVERSITY (US) 2022-07-05 US disclosed
US-11318140-B2 Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2022-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057808-A1 COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS ADH1A, ADH1C, SLC10A1 RIPK1 3703/4885ALDH1A1 41/4885CHRNB2 381/4885
US-20240228482-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER TP53, CASP3, BAX RIPK1 3410/4885ALDH1A1 338/4885CHRNB2 4602/4885
US-20220402938-A1 GLUTAMATE TRANSPORTER ACTIVATORS AND METHODS USING SAME SLC1A2, SLC1A1, SLC1A3 RIPK1 3458/4885ALDH1A1 1098/4885CHRNB2 345/4885
US-12162891-B2 Glutamate transporter activators and methods using same SLC1A2, SLC1A1, SLC1A3 RIPK1 3458/4885ALDH1A1 1098/4885CHRNB2 345/4885
US-20220267308-A1 Modulators of Excitatory Amino Acid Transporters and Methods Using Same SLC1A2, SLC1A1, SLC1A3 RIPK1 4588/4885ALDH1A1 1178/4885CHRNB2 354/4885
US-20250092001-A1 NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME SLC1A2, SLC1A3, SLC1A1 RIPK1 2731/4885ALDH1A1 1199/4885CHRNB2 287/4885
US-11377452-B2 Glutamate transporter activators and methods using same SLC1A2, SLC1A1, SLC1A3 RIPK1 3458/4885ALDH1A1 1098/4885CHRNB2 345/4885
US-20260146254-A1 Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications CD44, ADAR, TLR9 RIPK1 3164/4885ALDH1A1 1406/4885CHRNB2 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.